BR112023022432A2 - Formas cristalinas iv de sais de ácidos orgânicos de composto agonista do receptor de melanocortina, seus metódos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas - Google Patents

Formas cristalinas iv de sais de ácidos orgânicos de composto agonista do receptor de melanocortina, seus metódos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas

Info

Publication number
BR112023022432A2
BR112023022432A2 BR112023022432A BR112023022432A BR112023022432A2 BR 112023022432 A2 BR112023022432 A2 BR 112023022432A2 BR 112023022432 A BR112023022432 A BR 112023022432A BR 112023022432 A BR112023022432 A BR 112023022432A BR 112023022432 A2 BR112023022432 A2 BR 112023022432A2
Authority
BR
Brazil
Prior art keywords
organic acid
same
acid salts
crystalline
pharmaceutical compositions
Prior art date
Application number
BR112023022432A
Other languages
English (en)
Inventor
Yoon Kim Ji
Ah CHUN Seul
Won Kim Sung
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of BR112023022432A2 publication Critical patent/BR112023022432A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

formas cristalinas iv de sais de ácidos orgânicos de composto agonista do receptor de melanocortina, seus metódos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas. a presente invenção refere-se a uma forma cristalina iv de sais de ácidos orgânicos de um composto representado por fórmula química 1, a um método de preparação do mesmo e a uma composição farmacêutica compreendendo o mesmo. a forma cristalina iv de sais de ácidos orgânicos do composto representado por fórmula química 1 da presente invenção pode ser caracterizada por um padrão de drxp, um perfil de cdv e/ou um perfil de atg.
BR112023022432A 2021-05-07 2022-05-06 Formas cristalinas iv de sais de ácidos orgânicos de composto agonista do receptor de melanocortina, seus metódos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas BR112023022432A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210059133 2021-05-07
PCT/KR2022/006480 WO2022235106A1 (ko) 2021-05-07 2022-05-06 멜라노코르틴 수용체 작용제 화합물의 유기산 염의 결정형 ⅳ 및 이의 제조방법

Publications (1)

Publication Number Publication Date
BR112023022432A2 true BR112023022432A2 (pt) 2024-01-09

Family

ID=83932326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022432A BR112023022432A2 (pt) 2021-05-07 2022-05-06 Formas cristalinas iv de sais de ácidos orgânicos de composto agonista do receptor de melanocortina, seus metódos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas

Country Status (9)

Country Link
EP (1) EP4317151A1 (pt)
JP (1) JP2024517271A (pt)
KR (1) KR20220152164A (pt)
CN (1) CN117255788A (pt)
AU (1) AU2022271120A1 (pt)
BR (1) BR112023022432A2 (pt)
CA (1) CA3217468A1 (pt)
MX (1) MX2023013129A (pt)
WO (1) WO2022235106A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074679A1 (en) * 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
EP1368339A1 (en) * 2001-01-23 2003-12-10 Eli Lilly & Company Substituted piperidines/piperazines as melanocortin receptor agonists
AR044510A1 (es) 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
US7989634B2 (en) * 2003-11-12 2011-08-02 Lg Life Sciences Ltd. Melanocortin receptor agonists
TWI332501B (en) 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
BR112019016488B1 (pt) 2017-02-08 2022-11-16 Tilray, Inc Método e aparato para processamento de cannabis com energia radiante de baixa pressão
JP7467510B2 (ja) * 2019-11-07 2024-04-15 エルジー・ケム・リミテッド メラノコルチン－４受容体アゴニスト
KR20210059133A (ko) 2019-11-14 2021-05-25 한국철도기술연구원 무접점 제어 계전부를 포함하는 전기선로전환기

Also Published As

Publication number Publication date
AU2022271120A1 (en) 2023-11-09
KR20220152164A (ko) 2022-11-15
EP4317151A1 (en) 2024-02-07
WO2022235106A1 (ko) 2022-11-10
JP2024517271A (ja) 2024-04-19
CA3217468A1 (en) 2022-11-10
MX2023013129A (es) 2023-11-28
CN117255788A (zh) 2023-12-19

Similar Documents

Publication Publication Date Title
BR112012012947A2 (pt) forma cristalina e amorfa de hemitartarato genz 112638 como inibidor de glicosilceramida sintase
BRPI0816564B8 (pt) Composto, composição para proteger um animal de uma praga parasita invertebrada e método para proteger um animal de uma praga parasita invertebrada
BR112017019995A2 (pt) composto, composição, mistura herbicida e método de controle do crescimento de vegetação
BR112018000687A2 (pt) composto, composição e mistura herbicida e métodos para o controle do crescimento da vegetação indesejada
BR112016005389A8 (pt) composto, composição, método para o controle de uma praga invertebrada e semente
BR112017021859A2 (pt) ?composto, composição e mistura herbicida e método para o controle do crescimento de vegetação indesejada?
UY32025A (es) Derivados sustituídos de la 6-cloro-2-hidroxi-3-(3,4-dioxo-ciclobut-1-enil-amino)-n-metoxi-n-metil-bencen-sulfonamida, solvatos, hidratos o sales farmacéuticamente aceptables de los mismos, proceso de preparación, composiciones y aplicaciones.
BR112016012584A8 (pt) composto, composição herbicida, mistura herbicida e método para o controle do crescimento da vegetação indesejada
BR112018075297A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção bacteriana
BR112022022946A2 (pt) Sal e formas cristalinas de 4-amino-5-(6-(4-metilpiperazin-1-il)-1h-benzo[d]imidazol-2-il)tieno[2,3-b]piridin-6(7h)-ona
BR112019006023A2 (pt) forma cristalina, métodos de preparação da forma cristalina e do composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou enfermidade e para modular atividade de cinase.
BRPI0720742B8 (pt) derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos
CL2023001225A1 (es) Forma de cristal iv de compuesto agonista del receptor de melanocortina, y metodo de preparacion
BR112018012010A2 (pt) composto, composição, método de controle de pragas invertebradas e semente tratada
BR112017001439A2 (pt) ?composto, composição e mistura herbicida e métodos de controle do crescimento de vegetação?
BR112023022432A2 (pt) Formas cristalinas iv de sais de ácidos orgânicos de composto agonista do receptor de melanocortina, seus metódos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas
BR112015009326A2 (pt) Composto, composições herbicidas, mistura herbicida e método para controlar o crescimento de vegetação indesejada
BRPI1006006A8 (pt) Compostos, composição fungicida e método para o controle de fungos fitopatogênicos de culturas
PE20090736A1 (es) Derivados de macrolactona
BR112023024037A2 (pt) Sal farmaceuticamente aceitável de derivado de pirazoloheteroarila, formas cristalinas, composição farmacêutica, usos dos mesmos e métodos para preparar as referidas formas cristalinas e composição farmacêutica
BR112017018140A2 (pt) ?composto, composição fungicida e método de controle de doenças de plantas?
BR112023022334A2 (pt) Formas cristalinas de sulfato do composto agonista do receptor de melanocortina, seus métodos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas
AR078870A1 (es) Compuestos de pirazina fusionados como sus sales utiles para el tratamiento de enfermedades degenerativas e inflamatorias
BR112023022863A2 (pt) Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo
ECSP23086661A (es) Forma cristalina del compuesto derivado tricíclico, método para preparar la misma y composición farmacéutica que comprende la misma